A phase I trial of EZN‐4176, a second‐generation antisense oligonucleotide to exon 4 of the androgen receptor, has utilized the variations in CTC count to evaluate the drug efficacy in prostate cancer patients [104]. The gene discussed is AR; the disease is prostate carcinoma.